Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Meditsinskaia Tekhnika|December 10, 1998
[Structural approach to presentation and analysis of neuropsychological information]I P Lukashevich, K M Shipkova, V M Shklovskiĭ
Zhurnal Vysshei Nervnoi Deiatelnosti Imeni I P Pavlova|September 16, 1999
[The effect of afferent subcortical conduction pathways on speech function status]I P Lukashevich, K M Shipkova, V M Shklovskiĭ
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|December 1, 1999
[Prognostic criteria of speech rehabilitation in patients with sequelae after ischemic stroke]V M Shklovskiĭ, K M Shipkova, I P Lukashevich
Clinical Mass Spectrometry (Del Mar, Calif.)|August 28, 2024
Detection of drugs of abuse in urine using the Bruker Toxtyper™: Experiences in a routine clinical laboratory settingM Ott, K Berbalk, T Plecko, et al.
Clinical Chemistry and Laboratory Medicine|January 13, 2001
The monoethylglycinexylidide (MEGX) test as a marker of hepatic dysfunction in septic patients with pneumoniaA A Igonin, V W Armstrong, M Shipkova, et al.
Bone Marrow Transplantation|August 10, 2000
New strategies in GVHD prophylaxisM G Kiehl, M Shipkova, N Basara, et al.
Clinical Chemistry|June 13, 1998
Determination of monoethylglycinexylidide by fluorescence polarization immunoassay in highly icteric serum samples: modified precipitation procedure and HPLC comparedE Schütz, M Shipkova, P D Niedmann, et al.
Clinical Chemistry|March 7, 2000
Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and EmitM Shipkova, E Schütz, V W Armstrong, et al.
Therapeutic Drug Monitoring|February 25, 2000
Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant RecipientsM Oellerich, M Shipkova, E Schütz, et al.
Transplantation Proceedings|June 4, 2013
Total and free plasma concentrations of the active metabolite of leflunomide in relation to therapeutic outcome in kidney transplant recipients with BK-virus nephropathyM Hüttemann, M Shipkova, C Klett, et al.
Pageof 3